Tiger Brokers

BUZZ-Terns Pharma rises on early data for blood cancer drug

Reuters
Dec 03, 2024

** Shares of Terns Pharmaceuticals rise ~6% to $6.5 premarket

** Co says its experimental drug to treat a type of blood cancer showed clinically meaningful responses in patients at two lowest dose levels

** The drug, TERN-701, showed no dose-limiting toxicities across three completed dose levels, and no side-effect-related dose reductions or discontinuations - TERN

** TERN plans to share additional safety and efficacy data in late 2025

** The initial data was above expectations and supported long-term use, according to BMO Capital analysts

** TERN-701 is being developed to treat heavily pre-treated patients with relapsed/refractory chronic myeloid leukemia

** Up to last close, shares down ~5% YTD

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10